Le blocage androgénique intermittent versus continu dans le traitement du cancer de la prostate
|Advisor:||Turgeon-Fournier, Alexis; Vigneault, Éric|
|Abstract:||Intermittent androgen deprivation may offer several advantages over continuous androgen deprivation in the treatment of prostate cancer. However, it remains controversial. We thus conducted a systematic review and meta-analysis of randomized controlled trials to compare the effectiveness and tolerability of intermittent versus continuous androgen deprivation. A non-inferiority analysis was performed for overall survival with a pre specified margin of 1.15 for the upper boundary of the confidence interval (CI). Overall, 15 studies were eligible. Intermittent androgen deprivation was non-inferior to continuous androgen deprivation with a hazard ratio of 1.02 (95% CI: 0.93-1.11). There were minimal differences in global quality of life between the two interventions. However, more of the included studies observed an improvement in physical and sexual functioning with intermittent therapy. Intermittent androgen deprivation can be considered as an alternative option in patients with prostate cancer.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||24 April 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.